![Pharmaceutical Daily](https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/010/908/normal/Screenshot_2023-05-12_145055.png?1683899476)
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Pharmaceutical Daily,
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort
Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort